Hello NMPA: China Approval For Astellas's Xtandi, Keytruda Set For Fourth Indication
Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.
You may also be interested in...
Japanese firm unveils new capital investment program for novel biologics including antibodies and cell therapies as it ups full-year forecasts on strong US and global growth for Xtandi after a solid first half.
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.